The World Health Organization added its first monoclonal antibody, tocilizumab, to the WHO’s so-called pre-qualification list of medicines used as a benchmark for procurement by developing countries.

Eli Lilly

Eli Lilly said on Jan. 28 the company expects the U.S. Food and Drug Administration to decline the approval of expanded use of the rheumatoid arthritis drug Olumiant as a treatment for adults with moderate-to-severe eczema.

Cosentyx, Novartis

The U.S. Food and Drug Administration approved Novartis’
Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis in patients 4 years and older, and active psoriatic arthritis in patients 2 years and older.

Pfizer’s candidate treatment for patients diagnosed with active ankylosing spondylitis (AS) was approved by the U.S. Food and Drug Administration under a supplemental New Drug Application. 

The U.S. health regulator added the FDA’s strictest warning to the labels of drugs from Pfizer, Eli Lilly and AbbVie belonging to a class of anti-inflammatory treatments called JAK inhibitors, citing risk of serious health issues and death in patients 50 and over, the drugmakers said on December 3.

In a summary of some recent studies on Covid-19, an arthritis drug cuts the death risk in high-risk patients and heart medications might help prevent Covid-19 blood clots.

Indian drug developer Hetero received emergency use approval from the country’s health authorities to make a generic version of Roche Holding AG’s Covid-19 drug.

The Feinstein Institutes for Medical Research, the research unit of New York State health care provider Northwell Health, may have found a way to control neurons that drive inflammation.

Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.

The World Health Organization recommended using arthritis drugs Actemra from Roche and Kevzara from Sanofi with corticosteroids for Covid-19 patients after data from some 11,000 patients showed they cut the risk of death.